Objective: Investigate the safety and efficacy of 6 months' duodenal-jejunal bypass liner (DJBL) treatment in comparison with dietary intervention for obesity and type 2 diabetes mellitus (T2DM). Background: The DJBL is a bariatric procedure involving an impermeable sleeve that is delivered endoscopically in the proximal intestine. This procedure not only is less invasive than conventional surgical techniques but also has beneficial effects on obesity and T2DM. Methods: A multicenter randomized controlled trial was conducted. Seventyseven patients with obesity and T2DM were included. Thirty-eight patients were randomized to 6 months' DJBL treatment in combination with dietary intervention (34 successfully implanted, 31 completed the study), 39 patients received only dietary intervention (controls, 35 completed the study). Total study duration for both groups was 12 months, including 6 months of post-DJBL removal follow-up. Results: After 6 months, just before DJBL removal, the DJBL group had lost 32.0% [22.0%-46.7%] of their excess weight versus 16.4% [4.1%-34.6%] in the control group (P < 0.05). Glycated hemoglobin A 1c levels improved to 7.0% [6.4%-7.5%] in the DJBL group and to 7.9% [6.6%-8.3%] in the control group (P < 0.05). In addition, 85.3% of DJBL patients showed decreased postprandial glucose excursions versus 48.7% of control patients (P < 0.05). At 12 months, excess weight loss of the DJBL group was 19.8% [10.6%-45.0%] versus 11.7% [1.4%-25.4%] in the control group (P < 0.05). HbA 1c was 7.3% [6.6%-8.0%] versus 8.0% [6.8%-8.8%], DJBL versus control respectively (P = ns). Conclusions: The DJBL is a safe and effective alternative to invasive bariatric procedures. Six months of DJBL treatment combined with diet leads to superior weight loss and improvement of T2DM when compared with diet alone.
O besity is a rapidly growing problem worldwide. Once considered only a problem in Western society, obesity rates are now also rising dramatically in formerly developing countries. 1 Importantly, obesity is a major risk factor for several chronic diseases, including type 2 diabetes mellitus (T2DM) and cardiovascular diseases. 2 Furthermore, it is associated with impaired health-related quality of life. 3 Today, more than 500 million adults are overweight and millions of these people face the dual challenge of managing T2DM and obesity. 1, 4 Lifestyle changes resulting in weight loss improve T2DM and are, next to medication, the most important treatment modality for T2DM. Although conservative therapy is usually successful in weight control in the short term, long-term results are often disappointing. 5 Bariatric surgery, on the contrary, has proven its effectiveness in achieving and maintaining weight loss and improving T2DM, quality of life, and survival. [6] [7] [8] Surgery is increasingly performed and effective; however, it is associated with potentially important complications and, although rare, mortality. 9 Therefore, less invasive and safer techniques that will offer treatment of a broader spectrum of patients are searched for. 10 Recently, a novel nonsurgical bariatric technique has been developed, the duodenal-jejunal bypass liner (DJBL; GI Dynamics, Inc, Lexington, MA). The DJBL consists of a 60-cm long fluoropolymer liner that is delivered into and retrieved from the duodenum endoscopically. Its principle is based on the effectiveness of surgical duodenal-jejunal exclusion in treating obesity and T2DM; once placed in the duodenum, it mimics the intestinal bypass component of the well-known Roux-en-Y gastric bypass and surgical duodenaljejunal exclusion. Clinical experience to date has demonstrated the safety of the DJBL and its ability to rapidly improve blood glucose control and induce weight loss. [11] [12] [13] [14] [15] [16] In addition, the DJBL has been shown to improve other metabolic parameters, including lipid profile and blood pressure. [17] [18] [19] In the current randomized controlled study, we aimed to investigate the safety of 6 months' DJBL treatment and the effect on obesity, T2DM, and cardiovascular risk profile in obese patients with T2DM. After DJBL treatment, patients were followed up for 6 months to evaluate postremoval effects. pylori infection; probable insulin production failure as indicated by a C-peptide level of less than 1.0 ng/mL; iron deficiency or iron deficiency anemia; GI tract abnormalities or previous surgery in the GI tract that could affect the ability to place the device; symptomatic gallstones or kidney stones; known infection; bleeding disorders; gastroesophageal reflux disorder; connective tissue disorders; and severe liver or kidney failure as indicated by a creatinine level of more than 180 mmol/L.
Study Protocol
In a prospective, randomized, controlled, multicenter study, 77 patients were included in Rijnstate Hospital, Arnhem; Maastricht University Medical Center, Maastricht; and Atrium Medical Centrum Parkstad, Heerlen. As shown in Figure 1 , a total of 38 patients were randomized to the DJBL treatment group and 39 patients were randomized to the control group. Patients in the DJBL group were to be treated for 6 months with the DJBL and were followed up for an additional 6 months after removal of the device. Of the DJBL group, 34 patients received implants (3 failures, 1 withdrawal). Groups were comparable with respect to age, sex, BMI, and comorbidities (Table 1) .
At the initiation of the study, data on patient demographics, physical examination (including weight, BMI, and blood pressure), and medical history were collected. Electrocardiogram, chest radiograph, and abdominal ultrasonogram were obtained to rule out the presence of apparent pulmonary, cardiovascular, or GI disease. Laboratory parameters were obtained before the start of the treatment (HbA 1c , fasting glucose and insulin, total cholesterol, high-density cholesterol, low-density cholesterol, triglycerides, amylase, lipase, hemoglobin, hematocrit, iron, serum creatinine, vitamin D, calcium, FIGURE 1. Randomization chart. and C-peptide), and a 4-hour standard meal tolerance test was performed using a standard liquid meal (Ensure Plus vanilla flavor, Abbott Laboratories, Abbott Park, IL; 333 mL, 500 kcal, 20.8 g of protein, 67.3 g of carbohydrates, and 16.4 g of fat). During the study, all patients were prescribed a diet with a maximum of 1200 kcal for women and 1500 kcal for men, which was liquid for the first week. In addition, patients were advised to increase their physical activities. Medical treatment of T2DM was managed by a diabetes nurse under supervision of an endocrinologist. To avoid hypoglycemic events, the dose of glucose-lowering medication, except for metformin, was reduced by 50% at the time of implant or initiation of the diet. If hypoglycemic or hyperglycemic episodes were experienced, additional adaptations to the medical treatment were performed as regular. In addition, DJBL patients were prophylactically prescribed a proton pump inhibitor for the duration of DJBL treatment to prevent peptic ulcer formation in the stomach and the duodenum.
Regular follow-up visits were carried out at 1 week, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, and at 12 months. DJBL patients had an additional hospital visit 1 week after removal of the device. During these visits, weight and blood pressure were measured, adverse events were assessed, nutritional and diabetes counseling was performed, and blood was withdrawn to determine the same laboratory parameters as determined at the start of the study. The percentage of excess weight loss was calculated as follows: (Initial weight − Current weight)/Weight corresponding with BMI of 25 kg/m 2 . In addition, a standard 4-hour meal tolerance test was performed at 1 week and at 1, 3, and 6 months in both groups.
The study was conducted in accordance with the Standard ISO 14155: 2003 on clinical investigations with medical devices and the recommendations guiding physicians in biomedical research involving human patients adopted by the 18th World Medical Assembly, Helsinki, Finland, 1964 and later revisions. The study was approved by the medical ethical committee of all 3 participating hospitals. Before the start of the study, written informed consent was obtained from all patients.
DJBL Procedure
The DJBL is a single-use endoscopic device mimicking the intestinal bypass component of the Roux-en-Y gastric bypass ( Figs. 2A, B ). The device consist of a 60-cm long impermeable fluoropolymer liner and a nitinol anchor, which is used to reversibly affix the device to the duodenum (Figs. 2C, D). The anchor is located in the duodenal bulb, and the liner stretches out through the duodenum and the proximal part of the jejunum. To allow food passage, the DJBL is open at both the proximal and the distal end. As a result, chyme passes through the interior of the DJBL whereas pancreatic enzymes and bile pass on the outside of the liner. Digestion and absorption of nutrients therefore start at the end of the liner, creating a bypass of the proximal intestinal tract. Implantation of the DJBL was performed under general anesthesia with endotracheal intubation. Initial access to the stomach and the duodenum was achieved by standard gastroduodenoscopy. Next, a guide wire was advanced into the duodenum and the encapsulated device was tracked over the guide wire into the duodenum. The capsule at the distal end holds the liner and the anchor. The catheter has an atraumatic ball at the end, which is advanced through the intestine deploying the liner behind it. After full extension of the liner, the anchor was deployed in the duodenal bulb, approximately 0.5 cm distal to the pylorus. Endoscopic and fluoroscopic guidance was used to verify the correct position of the DJBL. Mean procedure time was 32 ± 4 minutes. After 6 months, the DJBL was removed as previously described. 15 anesthesia and 17 under conscious sedation. The mean procedure time of the removals was 11 ± 2 minutes.
Statistical Analysis
With a population of 35 subjects per group, a Fisher exact test using a 2-tailed α of 0.05 will have 80% power to achieve statistical significance between subject proportions of 25% (control) and 60% (device) achieving a 0.5% or more reduction in HbA 1c levels at month 6 or time of explant. In addition, with a sample size of 35 subjects per group, the probability of observing at least 1 occurrence of an adverse event will be 80% when the true probability of this event is 5.0%.
Analyses were performed on all patients randomized into the study and successfully treated with DJBL or diet with at least 1 follow-up visit. A univariate analysis using the Shapiro-Wilk test for normality suggested that several variables in the efficacy and other metabolic data were not normally distributed. Therefore, the median and interquartile ranges are presented of all efficacy, laboratory, and physiological variables. Wilcoxon rank sum tests were used to compare the difference between 2 groups for numeric variables. Proportions between the 2 groups were compared using the Fisher exact test. Missing data were not imputed. A P value less than 0.05 was considered statistically significant.
RESULTS

DJBL Versus Control: Effect on Weight
Baseline characteristics of both groups are shown in Table 1 
Effect of DJBL Versus Control Treatment on T2DM
Changes in Glucose-Lowering Medication
All participants used glucose-lowering medication at baseline. In the DJBL group (n = 38), 36 patients were taking metformin, 28 patients were taking SU derivatives, and 17 patients were taking insulin. In the control group (n = 39), 33 patients were taking met-formin, 30 patients were taking SU derivatives, and 19 patients were taking insulin.
Changes in glucose-lowering medication evaluated at month 6 and month 12 are displayed in Table 2 . Importantly, the daily insulin dosage was more often decreased or discontinued in the DJBL group versus control group, respectively (P = 0.79). Additional information on changes in high-density cholesterol, low-density cholesterol, and triglyceride levels is shown in Table 3 .
Effect of DJBL Versus Control Treatment on Cardiovascular Parameters
Safety Data
In the DJBL group, 76.3% of the patients had at least 1 adverse event versus 59% of the patients in the control group. In the DJBL group, adverse events consisted mainly of minor GI complaints, abdominal pain, or discomfort (63.2% in the DJBL group vs 28.2% in the control group, respectively). In the DJBL group, these complaints occurred primarily during the early postimplant phase, within 2 weeks after the implantation. Complaints of nausea or vomiting occurred in 23.7% of the DJBL patients and in 17.9% of the control patients. The prevalence of hypoglycemic events was comparable between the 2 groups: 23.7% in the DJBL versus 25.6% in the control group.
In the DJBL group, there were 8 adverse events requiring hospitalization. Five of the 8 events were device related. One patient presented with melena and pain in the epigastric region; however, no bleeding was found during endoscopic evaluation and complaints disappeared with conservative treatment. An additional patient presented with abdominal discomfort and subsequent dehydration due to insufficient fluid intake, which was also managed conservatively. In 1 patient, the DJBL was blocked with food, making early removal necessary. One patient suffered from symptomatic gallstones during the course of the study and was treated with laparoscopic cholecystectomy. All device-related serious adverse events resolved without sequelae. Only one procedure-related serious adverse event occurred, an esophageal perforation during a scheduled DJBL removal at month 6. After an apparent uncomplicated removal, final endoscopic evaluation revealed a 6-cm longitudinal, partially transmural tear of the esophagus. This was probably caused by one of the barbs on the anchor that was not fully covered by the removal hood. Treatment of the perforation was performed by endoscopic stenting and placement of a feeding tube. After 3 weeks, the tear had resolved without sequelae and the patient completed the study. During the study, only one DJBL patient withdrew consent because of an adverse event of abdominal pain at day 10. Two additional patients were lost to follow-up (at days 191 and 272, respectively; for more information see Fig. 1 ).
In the control group, there were also 8 adverse events requiring hospitalization. By the end of the study, 5 events had resolved without sequelae. The events that did not resolve without sequelae consisted of myocardial infarction, humerus fracture, lower back hernia, diagnosis of cancer, and a nonspecified psychiatric disorder. In this group, 4 patients withdrew informed consent. One patient each at week 1, month 3, and day 315, and 1 patient withdrew consent at day 273 when received a diagnosis of cancer. One patient was lost to followup at day 267.
DISCUSSION
There is overwhelming evidence that bariatric surgery promotes weight loss and improves glucose homeostasis. 20 Both Rouxen-Y gastric bypass and the biliopancreatic diversion seem to be the most effective procedures; both techniques cause significant weight loss and durable remission of T2DM. 8, [21] [22] [23] Interestingly, the improvement of T2DM occurs rapidly within days after both types of surgery. [23] [24] [25] This rapid glycemic improvement is thought to be specifically attributable to the intestinal bypass component, [26] [27] [28] which, according to the foregut hypothesis, results in glycemic improvement by reduced secretion of diabetogenic factors in the proximal small intestine. 26, 29 The hindgut hypothesis, on the contrary, attributes improved glycemic control to enhanced secretion of incretins in response to undigested nutrients in the distal small intestine. 27, 30 Interestingly, exclusion of the proximal small intestine by means of the surgical duodenal-jejunal bypass, rapidly improves T2DM, even in nonobese patients. 31 The DJBL is a nonsurgical endoscopic device developed to create an intestinal bypass in a minimally invasive way. 15, 32 Previous studies have revealed positive effects of the DJBL on obesity, T2DM, and the metabolic syndrome. [11] [12] [13] [14] [15] [16] [17] [18] [19] The aim of the current study was to investigate the effect of the DJBL on obesity and T2DM in a randomized manner, comparing 6 months of DJBL treatment in combination with dietary intervention with dietary treatment alone. This study is the first to report on 6 months of DJBL treatment compared with dietary intervention. Furthermore, our study included 6 months of post-DJBL removal follow-up.
Six months after treatment initiation, the DJBL group lost significantly more weight than the diet group. In addition, HbA 1c levels decreased significantly compared with the control group. DJBL treatment was associated with a greater percentage of patients achieving a decrease in postprandial glucose levels. Furthermore, glucoselowering medication was reduced or discontinued in more DJBL patients than in control patients. These results are in line with previous studies performed with the DJBL. Since the first report of a successful DJBL implant in a patient for a period of 3 months, resulting in a total weight loss of 9 kg, 33 several studies have demonstrated positive effects of DJBL treatment on obesity. 11, 18 In addition, a marked improvement of T2DM was observed. 11, 18 Previously performed randomized controlled trials, comparing DJBL treatment versus sham or diet control treatment, have displayed superiority of the DJBL in weight control and improvement of T2DM. [12] [13] [14] [15] Taken together, DJBL treatment in combination with a diet is more effective in treating obesity and T2DM than dietary intervention alone. Interestingly, the mechanisms responsible for the effectiveness of duodenal-jejunal exclusion are still unknown. Because postprandial insulin secretion seemed stable over the course of the study, it is tempting to speculate that the rapid changes in the glucose response to a meal may result from increased insulin sensitivity and/or decreased hepatic glucose production. 34 As previously shown, changes in glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon parallel this phenomenon. 16 Intraluminal implants in the digestive tract can theoretically be the cause of serious complications. Migration, bleeding, perforation, and obstruction are potential drawbacks and are reported often in numerous studies on stent placement for colonic malignancy. 35 Although design, indication, and placement behind the pylorus of the DJBL are unprecedented, safety has been a point of meticulous observation. However, DJBL treatment for 6 months has shown to have a favorable risk/benefit ratio. In the current study, one procedure-related event occurred, requiring only conventional treatment. Moreover, the early removal rate was low (1/34) in this study. Adverse events were mild and most commonly consisted of abdominal discomfort and nausea. They typically occurred during the first few weeks after DJBL implantation and usually resolved without treatment and without sequelae. So far no mortality has been reported after DJBL treatment, with a published experience of around 300 patients worldwide. Therefore, the DJBL can be considered as a safe treatment option for obesity and T2DM.
After removal of the device, weight and HbA 1c levels increased slightly in the DJBL group. A similar trend for weight and HbA 1c levels was observed in the control group. At month 12, the percentage of excess weight loss and the percentage of total weight loss were still significantly greater in the DJBL group. Changes in weight and HbA 1c levels were no longer statistically different between the groups. Importantly, weight and T2DM control remained improved compared with baseline in both groups. At the time of study initiation, the maximally approved DJBL treatment duration was 6 months in The Netherlands. de Moura et al 17 were the first to investigate 1-year DJBL treatment and demonstrated the safety and efficacy of the DJBL in reducing obesity and T2DM on the longer term. These positive effects have now been confirmed by 2 additional 1-year prospective clinical studies. 19, 36 On the basis of these results, it might be expected that the improvement in T2DM observed in the current study with a treatment duration of 6 months would be even more pronounced with a longer treatment duration. As DJBL is an innovative technique, the maximum potential of this device is as yet uncertain. One of the drawbacks could theoretically be migration of the device's anchor further into the duodenum. As the chance of migration potentially increases when the device is left in place for a longer period of time, implantation time is extended only gradually in order not to compromise the patients' safety. Next to longer implantation time, intermittent implantation could be a valid alternative to prolong the therapeutic effect of the DJBL and studies are now being conducted to evaluate the feasibility and efficacy of reimplantation. With regard to cardiovascular risk profile, as already described by Cohen et al, 36 subtle changes in cardiovascular risk profile can be of major clinical importance. In the current population, the 10-year risk for coronary heart disease according to the UK Prospective Diabetes Study Risk Engine would be, without intervention, approximately 14.0% in the DJBL group versus 12.5% in the control group at 12 months. With the DJBL intervention, the estimated 10-year coronary heart disease risk decreased by approximately 2% versus 1% decrease in the control group, 37 possibly indicating superiority of the DJBL over dietary treatment with respect to reducing risk for development of cardiovascular disease.
In the treatment algorithm for obese patients with type 2 diabetes, the DJBL can be positioned in between medical therapy and invasive bariatric techniques. In addition, it might be beneficial to combine DJBL treatment with the very promising glucoselowering therapies that have recently become available, such as glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors, or sodium/glucose cotransporter-2 inhibitors. 38 In the current study, no patients using these types of medication were included; however, studies including these drugs seem of great interest.
CONCLUSIONS
The current data suggest that the DJBL is a valid alternative to invasive bariatric procedures in the treatment of obesity and T2DM. Six months of DJBL treatment plus dietary intervention leads to significant weight loss and improvement of T2DM compared with dietary treatment alone.
